LMR Partners’s Altimmune ALT Stock Holding History

LMR Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250,000	Closed	-$903K	–	1438
2025 Q4	$903K	Hold	250,000	–	–	﹤0.01%	1011
2025 Q3	$943K	Sell	250,000 -102,800	-29%	-$397K	﹤0.01%	951
2025 Q2	$1.37M	Buy	+352,800	New	+$1.91M	0.01%	726

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LMR Partners's ALT Position: Q1 2026 in Review

LMR Partners sold out of Altimmune (ALT) in Q1 2026, closing a stake of 61,300 shares — an estimated $221K sold.

LMR Partners first reported a position in ALT in Q2 2017 and held it in 10 quarters. The position peaked at $455K in Q3 2021. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

LMR Partners reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
LMR Partners sold 61,300 Altimmune shares in Q1 2026, an estimated $221K.
LMR Partners first reported a position in Altimmune in Q2 2017 and held it in 10 quarters.
LMR Partners's Altimmune position peaked at $455K in Q3 2021.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.